MDAX

DGAP-News: Rocket Internet SE: Redemption of 1,572,340 own Shares completed

Friday, July 31, 2020 - 6:01pm

Berlin, July 31, 2020 - Rocket Internet SE (ISIN DE000A12UKK6) yesterday has redeemed 1,572,340 own shares and thus reduced the company's share capitalto EUR 135,690,619.00.

Key Points: 
  • Berlin, July 31, 2020 - Rocket Internet SE (ISIN DE000A12UKK6) yesterday has redeemed 1,572,340 own shares and thus reduced the company's share capitalto EUR 135,690,619.00.
  • Rocket Internet is listed on the Frankfurt Stock Exchange (ISIN DE000A12UKK6, RKET) and is included in the MDAX index.
  • The actual legal and economic interest of the Rocket Internet group in the network companies shown above is far lower than 100%.
  • Economic ownership figures include, where applicable, economic interest held through entities over which Rocket Internet has no control.

DGAP-News: CTS EVENTIM safeguards success of subsidiary Barracuda in midst of Austrian banking scandal

Friday, July 31, 2020 - 1:10pm

CTS EVENTIM, one of the leading international providers of ticketing services and live entertainment, is safeguarding the successful progress of its subsidiary Barracuda, Austria's biggest concert and festival promoter, against the backdrop of the scandal surrounding Commerzialbank Mattersburg, an Austrian bank.

Key Points: 
  • CTS EVENTIM, one of the leading international providers of ticketing services and live entertainment, is safeguarding the successful progress of its subsidiary Barracuda, Austria's biggest concert and festival promoter, against the backdrop of the scandal surrounding Commerzialbank Mattersburg, an Austrian bank.
  • Thanks to a comprehensive financing plan, the activities of the Barracuda Group are well protected, particularly its two flagship festivals, Nova Rock and Frequency.
  • CTS EVENTIM acquired a 71% stake in Barracuda Music at the start of this year.
  • CTS Eventim AG & Co. KGaA (ISIN DE 0005470306) has been listed on the stock exchange since 2000 and is currently a member of the MDAX segment.

DGAP-News: EVOTEC ENTERS PARTNERSHIP WITH QUANTRO THERAPEUTICS

Tuesday, July 21, 2020 - 7:00am

Hamburg, Germany, 21 July 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH ("QUANTRO"), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases.

Key Points: 
  • Hamburg, Germany, 21 July 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH ("QUANTRO"), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases.
  • By introducing "Transcriptional Fingerprinting" to drug discovery, QUANTRO intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts.
  • Both companies have acquired equal minority stakes in QUANTRO and will be represented on QUANTRO's Supervisory Board by Dr Dirk Ullmann (Evotec) and Dr Sebastian Kreuz (BIVF), respectively.
  • QUANTRO Therapeutics ("QUANTRO") is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases.

DGAP-News: CANCOM: Virtual General Meeting of CANCOM SE approves all proposed resolutions

Wednesday, July 1, 2020 - 9:00am

Munich, Germany, 1 July 2020 - At the virtual general meeting on 30 June 2020, the shareholders of CANCOM SE approved all proposed resolutions by a large majority.

Key Points: 
  • Munich, Germany, 1 July 2020 - At the virtual general meeting on 30 June 2020, the shareholders of CANCOM SE approved all proposed resolutions by a large majority.
  • The shareholders accepted the dividend proposal of EUR 0.50 per share, which remained constant compared to the previous year.
  • In addition, Mr. Uwe Kemm was elected to the Supervisory Board in line with the management's proposal.
  • CANCOM has an annual revenue of around EUR 1.5 billion and its parent company, CANCOM SE, is listed in the MDAX and TecDAX of the Frankfurt Stock Exchange (ISIN DE0005419105).

DGAP-News: EVOTEC SE VIRTUAL ANNUAL GENERAL MEETING 2020 APPROVES ALL PROPOSED AGENDA ITEMS

Tuesday, June 16, 2020 - 5:04pm

Hamburg, Germany, 16 June 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2020 with the required majority.

Key Points: 
  • Hamburg, Germany, 16 June 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2020 with the required majority.
  • Due to the COVID-19 pandemic, this year's Annual General Meeting was held as a purely virtual event.
  • All actions of the Management Board and the Supervisory Board were approved by the Annual General Meeting 2020 for the fiscal year 2019.
  • In total, 59.56% of the registered share capital was present at the virtual Annual General Meeting 2020.

DGAP-News: Deutsche Wohnen SE: Deutsche Wohnen moves up into the DAX

Friday, June 5, 2020 - 7:00am

From 22 June 2020, the Deutsche Wohnen share will be listed in the leading German share index DAX.

Key Points: 
  • From 22 June 2020, the Deutsche Wohnen share will be listed in the leading German share index DAX.
  • As Michael Zahn, CEO of Deutsche Wohnen, explains, "We are delighted to be moving up into the leading index on Germany's stock market.
  • Deutsche Wohnen SE is listed in the Deutsche Brse's MDAX and is also included in the leading indices EPRA/NAREIT, STOXX Europe 600, GPR 250 and DAX 50 ESG.
  • These statements express the intentions, opinions or current expectations and assumptions of Deutsche Wohnen and the individuals acting in concert with it.

DGAP-News: EVOTEC: CYPROTEX AWARDED NEW 5 YEAR AGREEMENT WITH THE US ENVIRONMENTAL PROTECTION AGENCY ('EPA')

Wednesday, June 3, 2020 - 7:02am

Hamburg, Germany, 03 June 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its wholly owned subsidiary Cyprotex US, LLC has been awarded a new 5 year contract with the US Environmental Protection Agency ("EPA").

Key Points: 
  • Hamburg, Germany, 03 June 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its wholly owned subsidiary Cyprotex US, LLC has been awarded a new 5 year contract with the US Environmental Protection Agency ("EPA").
  • The Toxicity Forecaster ("ToxCast"), launched in 2007, forms a major part of EPA's efforts to encourage the use of new approach methods to evaluate chemicals.
  • As of last year, ToxCast had evaluated a total of 3,800 chemicals including industrial chemicals, consumer products and food additives in over 700 high throughput assays.
  • Improving the prediction of chemical safety and toxicological risk is an important endeavour right across the life sciences sector.

DGAP-News: EVOTEC PARTICIPATES IN EXSCIENTIA'S FINANCING ROUND

Tuesday, May 26, 2020 - 7:01am

$ 60 M FINANCING ROUND INCLUDES NEW INVESTOR NOVO HOLDINGS AS WELL AS EXISTING INVESTORS EVOTEC, BRISTOL MYERS SQUIBB, AND GT HEALTHCARE CAPITAL

Key Points: 
  • $ 60 M FINANCING ROUND INCLUDES NEW INVESTOR NOVO HOLDINGS AS WELL AS EXISTING INVESTORS EVOTEC, BRISTOL MYERS SQUIBB, AND GT HEALTHCARE CAPITAL
    Hamburg, Germany, 26 May 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has participated in the Series C funding round of Exscientia, the world-leading Artificial Intelligence ("AI")-driven drug discovery company.
  • The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors' consortium consisting of Evotec, Bristol Myers Squibb, and GT Healthcare Capital also participating in the round.
  • Robert Ghenchev, Senior Partner and Head of Novo Growth, the growth equity arm of Novo Holdings, joins Exscientia's board of directors as part of the financing round.
  • Evotec and Exscientia, together, look forward to realising further synergistic potential in innovative drug discovery."

Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab

Wednesday, May 20, 2020 - 7:00pm

Incyte (NASDAQ:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody.

Key Points: 
  • Incyte (NASDAQ:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody.
  • Following the U.S. FDAs acceptance of our Biologics License Application filing for tafasitamab for Priority Review earlier this year, this represents another major step forward.
  • If approved, Incyte will hold the marketing authorization, and has exclusive commercialization rights for tafasitamab outside of the United States, including Europe.
  • In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally.

DGAP-News: MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab

Wednesday, May 20, 2020 - 7:02pm

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody.

Key Points: 
  • MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody.
  • "Following the U.S. FDA's acceptance of our Biologics License Application filing for tafasitamab for Priority Review earlier this year, this represents another major step forward.
  • If approved, Incyte will hold the marketing authorization, and has exclusive commercialization rights for tafasitamab outside of the United States, including Europe.
  • In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally.